Evaluation of Pharmacist Impact on Patients Initiating Eculizumab for Atypical Hemolytic Uremic Syndrome in the Inpatient Setting

Ann Pharmacother. 2023 Apr;57(4):506-507. doi: 10.1177/10600280221113830. Epub 2022 Jul 29.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Atypical Hemolytic Uremic Syndrome* / drug therapy
  • Humans
  • Inpatients*
  • Pharmacists

Substances

  • eculizumab
  • Antibodies, Monoclonal, Humanized